GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codexis Inc (NAS:CDXS) » Definitions » Shiller PE Ratio

CDXS (Codexis) Shiller PE Ratio : (As of Mar. 31, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Codexis Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Codexis Shiller PE Ratio Historical Data

The historical data trend for Codexis's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Codexis Shiller PE Ratio Chart

Codexis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Codexis Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Codexis's Shiller PE Ratio

For the Biotechnology subindustry, Codexis's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Codexis's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Codexis's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Codexis's Shiller PE Ratio falls into.


;
;

Codexis Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Codexis's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Codexis's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.13/133.1571*133.1571
=-0.130

Current CPI (Dec. 2024) = 133.1571.

Codexis Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -0.140 99.621 -0.187
201506 -0.140 100.684 -0.185
201509 0.130 100.392 0.172
201512 -0.050 99.792 -0.067
201603 -0.170 100.470 -0.225
201606 0.050 101.688 0.065
201609 0.030 101.861 0.039
201612 -0.130 101.863 -0.170
201703 -0.180 102.862 -0.233
201706 -0.130 103.349 -0.167
201709 -0.210 104.136 -0.269
201712 0.020 104.011 0.026
201803 -0.100 105.290 -0.126
201806 -0.070 106.317 -0.088
201809 -0.040 106.507 -0.050
201812 -0.010 105.998 -0.013
201903 -0.090 107.251 -0.112
201906 -0.120 108.070 -0.148
201909 0.010 108.329 0.012
201912 -0.010 108.420 -0.012
202003 -0.130 108.902 -0.159
202006 -0.110 108.767 -0.135
202009 -0.100 109.815 -0.121
202012 -0.060 109.897 -0.073
202103 -0.140 111.754 -0.167
202106 -0.070 114.631 -0.081
202109 0.030 115.734 0.035
202112 -0.160 117.630 -0.181
202203 -0.130 121.301 -0.143
202206 -0.040 125.017 -0.043
202209 -0.150 125.227 -0.159
202212 -0.190 125.222 -0.202
202303 -0.340 127.348 -0.356
202306 -0.170 128.729 -0.176
202309 -0.500 129.860 -0.513
202312 -0.100 129.419 -0.103
202403 -0.160 131.776 -0.162
202406 -0.320 132.554 -0.321
202409 -0.290 133.029 -0.290
202412 -0.130 133.157 -0.130

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Codexis  (NAS:CDXS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Codexis Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Codexis's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Codexis Business Description

Traded in Other Exchanges
Address
200 Penobscot Drive, Redwood City, CA, USA, 94063
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
Executives
Byron L Dorgan director C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Kevin Norrett officer: Chief Operating Officer C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Margaret Nell Fitzgerald officer: See Remarks ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Sriram Ryali officer: Chief Financial Officer C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Stephen George Dilly director, officer: See Remarks C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
John J Nicols director, officer: President and CEO ALBEMARLE CORP, 451 FLORIDA ST, BATON ROUGE LA 70801
H Stewart Parker director
Rahul Singhvi director 246 HOLLY DRIVE, CHALFONT PA 18914
Dennis P Wolf director 1101 EAST MEADOW DR, PALO ALTO CA 94303
Patrick Y Yang director C/O GENENTECH INC, 1 DNA WAY,MS 49,ATTN:K.STRAND OR J.BERRY, SOUTH SAN FRANCISCO CA 94080-4990
Bernard J Kelley director
Esther Martinborough director C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Jennifer Aaker director C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Alison Moore director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Thomas R Baruch director 1 LETTERMAN DRIVE, BUILDING C, SUITE CM500, SAN FRANCISCO CA 94129